IFNG and tuberculosis: These results highlight the feasibility of including immunocompromised populations, who are often underrepresented, in TB vaccine trials in support of equitable post-licensure access.Alemnew Dagnew (Gates MRI, USA) summarized results from the global epidemiological study, TBV02-E01 [NCT05190146], that assessed interferon gamma release assay (IGRA) positivity in high TB burden populations in 14 countries to identify eligible sites for the M72/AS01E Phase 3 trial [NCT06062238].